Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6796 to 6810 of 7710 results

  1. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development [GID-TA10575] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]

    Discontinued [GID-TA11176]

    Technology appraisal guidance
    Discontinued

  3. Osteoarthritis - diacerein [ID332]

    Discontinued [GID-TAG250]

    Technology appraisal guidance
    Discontinued

  4. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued [GID-TA10148]

    Technology appraisal guidance
    Discontinued

  5. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued [GID-TAG221]

    Technology appraisal guidance
    Discontinued

  6. Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]

    Discontinued [GID-TA11256]

    Technology appraisal guidance
    Discontinued

  7. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued [GID-TAG384]

    Technology appraisal guidance
    Discontinued

  8. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued [GID-TA11257]

    Technology appraisal guidance
    Discontinued

  9. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued [GID-TAG376]

    Technology appraisal guidance
    Discontinued

  10. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued [GID-TA10722]

    Technology appraisal guidance
    Discontinued

  11. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued [GID-TA11258]

    Technology appraisal guidance
    Discontinued

  12. Clostridium difficile associated diarrhoea - tolevamer [ID378]

    Discontinued [GID-TAG389]

    Technology appraisal guidance
    Discontinued

  13. Nintedanib for previously treated metastatic colorectal cancer [ID1030]

    Discontinued [GID-TA10138]

    Technology appraisal guidance
    Discontinued

  14. Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]

    In development [GID-TA10882] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development [GID-TA11272] Expected publication date: TBC

    Technology appraisal guidance
    In development